B. longum CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice

ABSTRACTThe gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of Bifidobacterium longum NBM7–1 (CKD1) with anti-diabetic medicines, LobeglitazoneⓇ (LO), SitagliptinⓇ (...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Won Jun Kim, Bum Ju Kil, Chaewon Lee, Tae Young Kim, Goeun Han, Yukyung Choi, Kyunghwan Kim, Chang Hun Shin, Seung-Young Park, Heebal Kim, Myunghoo Kim, Chul Sung Huh
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Taylor & Francis Group 2024-12-01
Seri Bilgileri:	Gut Microbes
Konular:	Bifidobacterium longum CKD1 anti-diabetic medicines IL-22 signaling insulin resistance hepatic steatosis
Online Erişim:	https://www.tandfonline.com/doi/10.1080/19490976.2024.2319889
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

B. longum CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice

Benzer Materyaller